These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1116 related items for PubMed ID: 23038639

  • 1. Differential expression of VEGF ligands and receptors in prostate cancer.
    Woollard DJ, Opeskin K, Coso S, Wu D, Baldwin ME, Williams ED.
    Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
    [Abstract] [Full Text] [Related]

  • 2. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V, Mukunyadzi P, Dennis RA, Siegel ER, Johnson DE, Kohli M.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [Abstract] [Full Text] [Related]

  • 3. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer.
    Zeng Y, Opeskin K, Baldwin ME, Horvath LG, Achen MG, Stacker SA, Sutherland RL, Williams ED.
    Clin Cancer Res; 2004 Aug 01; 10(15):5137-44. PubMed ID: 15297417
    [Abstract] [Full Text] [Related]

  • 4. Molecular control of lymphatic metastasis.
    Achen MG, Stacker SA.
    Ann N Y Acad Sci; 2008 Aug 01; 1131():225-34. PubMed ID: 18519975
    [Abstract] [Full Text] [Related]

  • 5. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis.
    Zeng Y, Opeskin K, Goad J, Williams ED.
    Cancer Res; 2006 Oct 01; 66(19):9566-75. PubMed ID: 17018613
    [Abstract] [Full Text] [Related]

  • 6. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Wedge SR, Jürgensmeier JM, Alitalo K.
    Cancer Res; 2008 Jun 15; 68(12):4754-62. PubMed ID: 18559522
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
    Davydova N, Harris NC, Roufail S, Paquet-Fifield S, Ishaq M, Streltsov VA, Williams SP, Karnezis T, Stacker SA, Achen MG.
    J Biol Chem; 2016 Dec 30; 291(53):27265-27278. PubMed ID: 27852824
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.
    Von Marschall Z, Scholz A, Stacker SA, Achen MG, Jackson DG, Alves F, Schirner M, Haberey M, Thierauch KH, Wiedenmann B, Rosewicz S.
    Int J Oncol; 2005 Sep 30; 27(3):669-79. PubMed ID: 16077915
    [Abstract] [Full Text] [Related]

  • 12. [Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma].
    Lu ZQ, Li HG, Xie DR, Zhang HZ, Shen XM, Zeng YJ, Zeng H.
    Ai Zheng; 2005 Sep 30; 24(9):1132-5. PubMed ID: 16159440
    [Abstract] [Full Text] [Related]

  • 13. Expression of vascular endothelial growth factors VEGF- C and D, VEGFR-3, and comparison of lymphatic vessels density labeled with D2-40 antibodies as a prognostic factors in vulvar intraepithelial neoplasia (VIN) and invasive vulvar cancer.
    Jach R, Dyduch G, Radon-Pokracka M, Przybylska P, Mika M, Dulinska-Litewka J, Zajac K, Huras H, Streb J, Stangel-Wojcikiewicz K, Dziadek O, Galarowicz B.
    Neuro Endocrinol Lett; 2011 Sep 30; 32(4):530-9. PubMed ID: 21876509
    [Abstract] [Full Text] [Related]

  • 14. Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.
    Feng Y, Wang W, Hu J, Ma J, Zhang Y, Zhang J.
    Anat Rec (Hoboken); 2010 May 30; 293(5):802-12. PubMed ID: 20225197
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
    Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB.
    J Pathol; 2003 Jun 30; 200(2):183-94. PubMed ID: 12754739
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Lymphangiogenesis in aortic valve stenosis--novel regulatory roles for valvular myofibroblasts and mast cells.
    Syväranta S, Helske S, Lappalainen J, Kupari M, Kovanen PT.
    Atherosclerosis; 2012 Apr 30; 221(2):366-74. PubMed ID: 22281299
    [Abstract] [Full Text] [Related]

  • 20. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
    Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T, Koizumi F.
    Breast Cancer Res; 2011 Jun 21; 13(3):R66. PubMed ID: 21693010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.